Novavax Inc (NAS:NVAX)

$ 9.44 0.32 (3.51%) Market Cap: 1.51 Bil Enterprise Value: 643.71 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 69/100

Q2 2024 Novavax Inc Earnings Call Transcript

Aug 08, 2024 / 12:30PM GMT

Release Date Price: $11.68 (+9.06%)

Transcript 8-K10-Q

Key Points

Positve

Novavax Inc (NVAX) has secured a significant partnership with Sanofi, which includes an upfront payment and equity investment of approximately $570 million.
The company is on track to initiate a Phase 3 trial for its standalone influenza and COVID-19 influenza combination vaccines, with top-line data expected by mid-2025.
Novavax Inc (NVAX) is transitioning to a more efficient R&D model, focusing on leveraging its proven technology platform for additional partnerships and deals.
The company has reduced its R&D and SG&A expenses by 34% compared to the previous year, aligning with its goal to become a leaner organization.
Novavax Inc (NVAX) has secured contracts with major US retail pharmacies, increasing the availability of its COVID-19 vaccine for the upcoming vaccination season.

Negative

The company is facing challenges in renegotiating or exiting APA agreements due to declining global COVID-19 vaccination rates.
Novavax Inc (NVAX) has reduced its full-year 2024 product sales guidance due to issues with the New Zealand APA and lower-than-expected EU commercial sales.
The company is undergoing a transition that requires patience from stakeholders as it shifts focus from a single product to multiple potential growth drivers.
There is uncertainty regarding the timing and outcome of regulatory approvals for its updated COVID-19 vaccine formulation.
Novavax Inc (NVAX) is exploring the sale of its Czech Republic manufacturing facility, indicating potential operational downsizing.

Operator

Good morning, and welcome to Novavax second-quarter 2024 financial results and operational highlights conference call. (Operator Instructions). Please note, this event is being recorded.

I would now like to turn the call over to your speaker today, Erika Schultz, Senior Director, Investor Relations. Please go ahead.

Erika Schultz

Novavax Inc - Senior Director, Investor Relations

Good morning, and thank you, all, for joining us today to discuss our second-quarter 2024 operational highlights and financial results. A press release announcing our results is currently available on our website at novavax.com, and an audio archive of this conference call will be available on our website later today.

Please turn to slide 2. Before we begin with prepared remarks, I need to remind you that this presentation includes forward-looking statements, including information relating to the future of Novavax; its key strategic priorities; statements related to potential royalties and milestones; operating plans, objectives, and prospects; full-year 2024

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.